CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE) May 22, 2020 –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved Alunbrig (brigatinib) for adult patients with…Original Article
FDA Approves Takeda’s Alunbrig (brigatinib) as a First-Line Treatment Option for Patients with ALK+ Metastatic Non-Small Cell Lung Cancer (NSCLC)
